Table 1.
Clinical trials exploring second-line chemotherapy.
| Study | Treatment | N of pts | Major toxicities | Progression-free survival HR (95%CI) | Overall survival HR (95% CI) |
|---|---|---|---|---|---|
| TAX317 (20) | Docetaxel (100 or 75 mg/m2) vs best supportive care | 103 | Leukopenia, neutropenia, hair loss | – | p = 0.01 |
| TAX320 (21) | Docetaxel (100 or 75 mg/m2) vs vinorelbine or ifosfamide | 373 | Leukopenia, neutropenia, hair loss for docetaxel | p = 0.005 | 5.5 vs 5.7 m (NS) |
| DISTAL-01 (22) | Docetaxel (75 mg/m2 q21) vs docetaxel (33 mg/m2 weekly) | Weekly: non-neutropenic infection | – | HR 1.04 (0.77–1.39) p = 0.80 | |
| 3-weekly: leukopenia, neutropenia, hair loss | |||||
| JMEI (23) | Pemetrexed (500 mg/m2) vs docetaxel (75 mg/m2) | Leukopenia, neutropenia, hair loss for docetaxel | HR 0.97 (0.82–1.16) | HR 0.99 (0.8–1.20) |
NS, not significant; HR, hazard ratio.